Respiratory Syncytial Virus Vaccine Market Size, Trends and Insights By Age Group (Pediatric, Adult), By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), By Distribution Channel (Hospital & Others Pharmacies, Government Suppliers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- AstraZeneca plc
- GlaxoSmithKline plc (GSK)
- Novavax Inc.
- Pfizer Inc.
- Moderna Inc.
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global Respiratory Syncytial Virus Vaccine Market is expected to record a CAGR of 4.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 1.2 billion. By 2032, the valuation is anticipated to reach USD 2.2 billion.
The Respiratory Syncytial Virus (RSV) Vaccine Market pertains to the pharmaceutical sector’s endeavors to combat RSV, a common virus causing respiratory infections, especially in infants and the elderly. The market nature is dynamic, marked by rigorous research, clinical trials, and collaboration among pharmaceutical giants.
Past trends were driven by heightened awareness of RSV risks, while present trends focus on pediatric vaccination, advanced vaccine technologies, and heightened global demand, notably following the COVID-19 pandemic, highlighting the growing importance of respiratory health solutions.
Respiratory Syncytial Virus Vaccine Market – Significant Growth Factors
The Respiratory Syncytial Virus Vaccine Market presents significant growth opportunities due to several factors:
- High Disease Burden: The significant prevalence of RSV infections, especially among vulnerable populations like infants and the elderly, presents a strong driver for vaccine development and market growth.
- Pediatric Vaccination: The increasing emphasis on pediatric vaccination programs and the inclusion of RSV vaccines in childhood immunization schedules create a substantial market opportunity.
- Advancements in Vaccine Technology: Innovations in vaccine formulation, adjuvants, and delivery methods are driving the development of more effective and convenient RSV vaccines, enhancing market prospects.
- Global Pandemic Preparedness: The COVID-19 pandemic has underscored the need for comprehensive respiratory health solutions, increasing demand for RSV vaccines as part of preparedness measures.
- Aging Population: As the global population ages, the elderly become a more significant target demographic for RSV vaccination, creating a growing market segment.
- Public Health Initiatives: Government initiatives and healthcare organizations’ efforts to raise awareness about RSV-related health risks and promote vaccination contribute to market expansion, creating opportunities for vaccine manufacturers and developers.
Respiratory Syncytial Virus Vaccine Market – Mergers and Acquisitions
The Respiratory Syncytial Virus Vaccine Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their Age Group offerings and profitability. Some notable examples of mergers and acquisitions in the Respiratory Syncytial Virus Vaccine Market include:
- In 2023, an affiliate affiliated with the Cyrus Poonawalla Group, in partnership with the Serum Institute of India, a leading biotechnology company with expertise in vaccine production, attained official regulatory clearance for the creation of a versatile vaccine. This pioneering vaccine is designed to address a wide range of illnesses, encompassing polio, tetanus, diphtheria, hepatitis B, mumps, measles, and rubella.
- In 2023, Direct Relief unveiled the recipients of its prestigious Innovation Awards in Community Health. These awards highlighted innovative projects focused on addressing infectious diseases in underserved communities. The honorees emphasized pioneering approaches in vaccine distribution and education, offering vital support to safety-net healthcare providers in the community.
- In 2023, the Beijing Center for Disease Prevention and Control inaugurated the Beijing Major Respiratory Epidemic Disease Center. This cutting-edge research facility is dedicated to advancing our understanding of disease transmission, rapid diagnostic methods, effective control strategies, and early warning systems. Its primary mission revolves around enhancing epidemic disease management and containment efforts.
- In 2023, GSK plc achieved a significant milestone when it obtained approval from the FDA for Arexvy, marking the world’s inaugural global approval for an RSV vaccine intended for the elderly population.
These mergers and acquisitions have helped companies expand their Age Group offerings, improve their market presence, and capitalize on growth opportunities in the Respiratory Syncytial Virus Vaccine Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Respiratory Syncytial Virus Vaccine Market | Pharmaceutical Elixir Market | Retail Pharmacy Market |
| CAGR 4.6% (Approx) | CAGR 9% (Approx) | CAGR 7.1% (Approx) |
| USD 2.2 Billion by 2032 | USD 11.56 Billion by 2032 | USD 1,215.4 Billion by 2032 |
Respiratory Syncytial Virus Vaccine Market – Significant Threats
The Respiratory Syncytial Virus Vaccine Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Scientific Complexity: RSV is a complex virus, and developing an effective vaccine has proven challenging due to its multiple strains and the need for durable immunity.
- Regulatory Hurdles: Meeting stringent regulatory requirements for vaccine approval can be time-consuming and costly, potentially delaying market entry.
- Competitive Landscape: The market is highly competitive, with established pharmaceutical companies and newcomers vying for market share.
- Vaccine Hesitancy: Public concerns and misinformation about vaccine safety and efficacy can hinder adoption rates, especially in pediatric populations.
- Global Health Disparities: Access to vaccines may be limited in low-income regions, leading to disparities in RSV prevention and treatment.
- Emerging Variants: Like other viruses, RSV can mutate, potentially reducing the effectiveness of existing vaccines and necessitating updates.
- Production Challenges: Scalable vaccine production can be complex, leading to supply chain issues and potential shortages.
- Economic Factors: Economic downturns or budget constraints in healthcare systems can affect funding for RSV vaccination programs.
- Co-Infections: RSV often co-occurs with other respiratory pathogens, complicating diagnosis and treatment.
- Seasonal Variability: RSV tends to have seasonal outbreaks, impacting the timing and demand for vaccines.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 1.3 Billion |
| Projected Market Size in 2032 | USD 2.2 Billion |
| Market Size in 2022 | USD 1.2 Billion |
| CAGR Growth Rate | 4.6% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Age Group, Type, Distribution Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Category-Wise Insights
By Age Group:
- Pediatric: Within the Respiratory Syncytial Virus (RSV) Vaccine Market, the pediatric segment concentrates on safeguarding infants and young children from RSV. Ongoing trends encompass the creation of RSV vaccines tailored for pediatric use, heightened awareness regarding RSV-related risks among youngsters, and initiatives to integrate RSV vaccination seamlessly into routine childhood immunization programs.
- Adult: In the context of the Respiratory Syncytial Virus (RSV) Vaccine Market, the adult category encompasses individuals beyond childhood who remain susceptible to RSV infections. Current market dynamics prioritize the expansion of RSV vaccine research and adoption among adults, recognizing the critical role of preventing RSV-induced respiratory ailments within this demographic.
By Type
- Viral Vaccine: These biological products stimulate immune responses against specific viruses, preventing infections. In the RSV Vaccine Market, ongoing trends revolve around advancing pediatric immunization, innovative vaccine technologies, and increased demand spurred by the COVID-19 pandemic. These developments aim to provide more effective solutions against respiratory syncytial virus infections.
- Bacterial Vaccine: These immunizations are designed to safeguard against bacterial infections. In the Respiratory Syncytial Virus (RSV) Vaccine Market, prevailing trends encompass the exploration of inventive vaccine technologies, a heightened focus on pediatric vaccination, and rising demand due to increased awareness of respiratory health, catalyzed by the COVID-19 pandemic.
- Combination Vaccine: These encompass single vaccines that offer protection against multiple diseases. In the Respiratory Syncytial Virus (RSV) Vaccine Market, a burgeoning trend centers on creating combination vaccines that not only target RSV but also address other respiratory pathogens. These vaccines provide comprehensive protection and convenience within a single immunization, potentially boosting acceptance in the market.
By Distribution Channel
- Hospital & Others Pharmacies: Hospital pharmacies are within medical facilities, while retail pharmacies are standalone outlets. In the RSV Vaccine Market, hospital pharmacies focus on vaccination during hospitalization. Retail pharmacies offer vaccines to the general public. Current trends include expanded access to RSV vaccines at retail locations and increased awareness, driving demand in both settings.
- Government Suppliers: Government suppliers in the Respiratory Syncytial Virus (RSV) Vaccine Market refer to entities that provide RSV vaccines directly to government healthcare programs. Current trends include governments worldwide expanding vaccination initiatives for at-risk populations, increasing procurement of RSV vaccines, and fostering partnerships with pharmaceutical companies to ensure wider vaccine availability.
Respiratory Syncytial Virus Vaccine Market – Regional Analysis
The Respiratory Syncytial Virus Vaccine Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: North America, comprising the United States and Canada, assumes a central position. Current market dynamics include the amplification of pediatric vaccination programs, the integration of cutting-edge vaccine technologies, and a committed effort to curtail RSV-associated hospitalizations. The market’s expansion is propelled by the considerable prevalence of RSV infections and substantial investments in healthcare infrastructure.
- Europe: Within the realm of the RSV Vaccine Market, Europe signifies the collective efforts of European nations to combat RSV infections. Recent market trends encompass an increasing emphasis on pediatric RSV vaccination, the incorporation of cutting-edge vaccine technologies, and regulatory approvals for RSV vaccines, showcasing a growing commitment to respiratory health.
- Asia-Pacific: The Asia-Pacific region is witnessing a surge in demand within the RSV Vaccine Market, driven by rising awareness, the expansion of healthcare infrastructure, and government-led initiatives. Prominent trends in this region include an intensified focus on pediatric vaccination and continual advancements in vaccine technology, both serving as pivotal factors propelling market growth.
- LAMEA: Recent developments reveal heightened awareness and substantial investments in healthcare infrastructure, sparking increased demand for RSV vaccines in the LAMEA region. Market expansion is propelled by a heightened incidence of RSV cases, endeavors targeting pediatric vaccination, and the enhancement of healthcare accessibility throughout the region.
Competitive Landscape – Respiratory Syncytial Virus Vaccine Market
The Respiratory Syncytial Virus Vaccine Market is highly competitive, with a large number of manufacturers and others operating globally. Some of the key players in the market include:
- AstraZeneca plc
- GlaxoSmithKline plc (GSK)
- Novavax Inc.
- Pfizer Inc.
- Moderna Inc.
- Sanofi Pasteur
- Merck & Co. Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Bavarian Nordic
- MedImmune (a subsidiary of AstraZeneca)
- Others
These companies operate in the market through various strategies such as application innovation, mergers and acquisitions, and partnerships.
Emerging contenders like Novavax, Moderna, and smaller biotech innovators such as Novadigm Therapeutics have made notable strides in entering the Respiratory Syncytial Virus (RSV) Vaccine Market through novel approaches.
Yet, market dominators like AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi Pasteur maintain their lead due to substantial investments in research, robust manufacturing capabilities, and expansive global distribution networks. These industry giants have further cemented their positions through strategic collaborations and acquisitions, rendering it challenging for newcomers to compete on a similar scale. Nevertheless, innovation remains a vital catalyst for shaping the market’s trajectory.
The Respiratory Syncytial Virus Vaccine Market is segmented as follows:
By Age Group
- Pediatric
- Adult
By Type
- Viral Vaccine
- Bacterial Vaccine
- Combination Vaccine
By Distribution Channel
- Hospital & Other Pharmacies
- Government Suppliers
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Respiratory Syncytial Virus Vaccine Market, (2024 – 2033) (USD Billion)
- 2.2 Global Respiratory Syncytial Virus Vaccine Market: snapshot
- Chapter 3. Global Respiratory Syncytial Virus Vaccine Market – Industry Analysis
- 3.1 Respiratory Syncytial Virus Vaccine Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 High Disease Burden
- 3.2.2 Pediatric Vaccination
- 3.2.3 Advancements in Vaccine Technology
- 3.2.4 Global Pandemic Preparedness
- 3.2.5 Aging Population
- 3.2.6 Public Health Initiatives.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Age Group
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- Chapter 4. Global Respiratory Syncytial Virus Vaccine Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Respiratory Syncytial Virus Vaccine Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Respiratory Syncytial Virus Vaccine Market – Age Group Analysis
- 5.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Age Group
- 5.1.1 Global Respiratory Syncytial Virus Vaccine Market Share, By Age Group, 2022 and – 2033
- 5.2 Pediatric
- 5.2.1 Global Respiratory Syncytial Virus Vaccine Market by Pediatric, 2024 – 2033 (USD Billion)
- 5.3 Adult
- 5.3.1 Global Respiratory Syncytial Virus Vaccine Market by Adult, 2024 – 2033 (USD Billion)
- 5.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Age Group
- Chapter 6. Global Respiratory Syncytial Virus Vaccine Market – Type Analysis
- 6.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Type
- 6.1.1 Global Respiratory Syncytial Virus Vaccine Market Share, By Type, 2022 and – 2033
- 6.2 Viral Vaccine
- 6.2.1 Global Respiratory Syncytial Virus Vaccine Market by Viral Vaccine, 2024 – 2033 (USD Billion)
- 6.3 Bacterial Vaccine
- 6.3.1 Global Respiratory Syncytial Virus Vaccine Market by Bacterial Vaccine, 2024 – 2033 (USD Billion)
- 6.4 Combination Vaccine
- 6.4.1 Global Respiratory Syncytial Virus Vaccine Market by Combination Vaccine, 2024 – 2033 (USD Billion)
- 6.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Type
- Chapter 7. Global Respiratory Syncytial Virus Vaccine Market – Distribution Channel Analysis
- 7.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Distribution Channel
- 7.1.1 Global Respiratory Syncytial Virus Vaccine Market Share, By Distribution Channel, 2022 and – 2033
- 7.2 Hospital & Others Pharmacies
- 7.2.1 Global Respiratory Syncytial Virus Vaccine Market by Hospital & Other Pharmacies, 2024 – 2033 (USD Billion)
- 7.3 Government Suppliers
- 7.3.1 Global Respiratory Syncytial Virus Vaccine Market by Government Suppliers, 2024 – 2033 (USD Billion)
- 7.1 Global Respiratory Syncytial Virus Vaccine Market Overview: By Distribution Channel
- Chapter 8. Respiratory Syncytial Virus Vaccine Market – Regional Analysis
- 8.1 Global Respiratory Syncytial Virus Vaccine Market Regional Overview
- 8.2 Global Respiratory Syncytial Virus Vaccine Market Share, by Region, 2022 & – 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America Respiratory Syncytial Virus Vaccine Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.4 North America Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033
- 8.4.1 North America Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033 (USD Billion)
- 8.5 North America Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033
- 8.5.1 North America Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033 (USD Billion)
- 8.6 North America Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033
- 8.6.1 North America Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033 (USD Billion)
- 8.7. Europe
- 8.7.1 Europe Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.7.1.1 Europe Respiratory Syncytial Virus Vaccine Market, by Country, 2024 – 2033 (USD Billion)
- 8.7.1 Europe Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.8 Europe Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033
- 8.8.1 Europe Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033 (USD Billion)
- 8.9 Europe Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033
- 8.9.1 Europe Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033 (USD Billion)
- 8.10 Europe Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033
- 8.10.1 Europe Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033 (USD Billion)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.11.1.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Country, 2024 – 2033 (USD Billion)
- 8.11.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.12 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033
- 8.12.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033 (USD Billion)
- 8.13 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033
- 8.13.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033 (USD Billion)
- 8.14 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033
- 8.14.1 Asia Pacific Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033 (USD Billion)
- 8.15. Latin America
- 8.15.1 Latin America Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.15.1.1 Latin America Respiratory Syncytial Virus Vaccine Market, by Country, 2024 – 2033 (USD Billion)
- 8.15.1 Latin America Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.16 Latin America Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033
- 8.16.1 Latin America Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033 (USD Billion)
- 8.17 Latin America Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033
- 8.17.1 Latin America Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033 (USD Billion)
- 8.18 Latin America Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033
- 8.18.1 Latin America Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033 (USD Billion)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.19.1.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Country, 2024 – 2033 (USD Billion)
- 8.19.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, 2024 – 2033 (USD Billion)
- 8.20 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033
- 8.20.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Age Group, 2024 – 2033 (USD Billion)
- 8.21 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033
- 8.21.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Type, 2024 – 2033 (USD Billion)
- 8.22 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033
- 8.22.1 The Middle-East and Africa Respiratory Syncytial Virus Vaccine Market, by Distribution Channel, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 AstraZeneca plc
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 GlaxoSmithKline plc (GSK)
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Novavax Inc.
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Pfizer Inc.
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Moderna Inc.
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Sanofi Pasteur
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Merck & Co. Inc.
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Johnson & Johnson (Janssen Pharmaceuticals)
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Bavarian Nordic
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 MedImmune (a subsidiary of AstraZeneca)
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Others.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.1 AstraZeneca plc
List Of Figures
Figures No 1 to 23
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- AstraZeneca plc
- GlaxoSmithKline plc (GSK)
- Novavax Inc.
- Pfizer Inc.
- Moderna Inc.
- Sanofi Pasteur
- Merck & Co. Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Bavarian Nordic
- MedImmune (a subsidiary of AstraZeneca)
- Others
FAQs
The key factors driving the Market are High Disease Burden, Pediatric Vaccination, Advancements in Vaccine Technology, Global Pandemic Preparedness, Aging Population And Public Health Initiatives.
The “Age Group” category dominated the market in 2022.
The key players in the market are AstraZeneca plc, GlaxoSmithKline plc (GSK), Novavax Inc., Pfizer Inc., Moderna Inc., Sanofi Pasteur, Merck & Co. Inc., Johnson & Johnson (Janssen Pharmaceuticals), Bavarian Nordic, MedImmune (a subsidiary of AstraZeneca), Others.
“Europe” had the largest share in the Respiratory Syncytial Virus Vaccine Market.
The global market is projected to grow at a CAGR of 4.6% during the forecast period, 2023-2032.
The Respiratory Syncytial Virus Vaccine Market size was valued at USD 1.2 Billion in 2022.